Drug intelligence / Profile preview

terpinen-4-ol + sodium hyaluronate

Development stage: Preclinical
Lead developer: NTC Pharma
Modality: Small Molecules
Administration: Ophthalmic, Topical

Overview

Terpinen-4-ol + sodium hyaluronate is a combination drug used primarily for ocular conditions. Terpinen-4-ol is the main bioactive component of tea tree oil with antimicrobial, anti-inflammatory, and potential anticancer properties. It effectively eradicates Demodex mites on eyelids and has shown efficacy in treating Demodex blepharitis. Sodium hyaluronate is a form of hyaluronic acid that provides hydration and lubrication to the ocular surface. The combination may be particularly effective for treating blepharitis and other ocular surface conditions.

Brand names: Blephademodex
Other names: T1172T-1172T 1172

Targets

Demodex mite cellular membrane

Beyond the preview

Go deeper on terpinen-4-ol + sodium hyaluronate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on terpinen-4-ol + sodium hyaluronate.

Explore the full profile